Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Gilead Sciences (GILD) and reduced the price target from $80 to $78.

April 26, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Gilead Sciences and lowers the price target from $80 to $78.
The reduction in price target by Morgan Stanley, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in GILD's stock price. The Equal-Weight rating suggests that the analyst sees the company as adequately valued at its current price, but the lowered target indicates a slight bearish outlook on the stock's future performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100